Submit New Drug Application for MT1621 in TK2 deficiency
Deadline passed; outcome being checked
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2022
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Planned New Drug Application (NDA) submission in first half of 2022 for MT1621 in TK2 deficiency”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- MT1621 NDA for TK2 deficiency
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Zogenix, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C375151-024545 · Corrections policy